Caricamento...
Experience with ibrutinib for first-line use in patients with chronic lymphocytic leukemia
Ibrutinib is the first in-class, orally administered, Bruton’s tyrosine kinase (BTK) inhibitor that abrogates the critical signaling downstream of the B-cell receptor (BCR). This signaling is required for B-cell survival, proliferation and interaction with the microenvironment. Ibrutinib proved acti...
Salvato in:
| Pubblicato in: | Ther Adv Hematol |
|---|---|
| Autori principali: | , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
SAGE Publications
2017
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5753924/ https://ncbi.nlm.nih.gov/pubmed/29317997 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2040620717741861 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|